NCT04743453View on ClinicalTrials.gov

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

PHASE4CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

September 2, 2024

Study Completion Date

September 2, 2024

Conditions
Kidney TransplantationDiabetes Mellitus, Type 2Diabetes Complications
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.

DRUG

Placebo

Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.

Trial Locations (1)

05403900

Hospital das Clinicas - FMUSP, São Paulo

All Listed Sponsors
collaborator

Federal University of São Paulo

OTHER

lead

University of Sao Paulo General Hospital

OTHER

NCT04743453 - EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS. | Biotech Hunter | Biotech Hunter